AEON Biopharma (AEON) vs Chemomab Therapeutics (CMMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Chemomab Therapeutics (CMMB) has outperformed AEON Biopharma (AEON) over the past year, losing 53.0% versus a loss of 85.2%. AEON Biopharma is the larger company by market cap ($10.3 million vs $9.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | CMMB |
|---|---|---|
| Share price | $0.123 | $1.19 |
| Market cap | $10.35M | $9.58M |
| 1-day change | -7.59% | +4.39% |
| YTD return | -88.82% | -27.88% |
| 1-year return | -85.18% | -52.96% |
| 5-year return | — | -96.65% |
| EPS (TTM) | $-3.89 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-39.22M | $-8.99M |
| 52-week high | $1.45 | $2.99 |
| 52-week low | $0.106 | $0.92 |
| Distance from 52-week high | -91.52% | -60.20% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1379.67% | +320.17% |
| Average volume | 7.44M | 102.39K |
| Shares outstanding | 84.12M | 8.05M |
| Employees | 8 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMMB has outperformed AEON by 32.2 percentage points over the past year.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations
AEON vs CMMB FAQ
Which is bigger, AEON Biopharma or Chemomab Therapeutics?
AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $9.58M for Chemomab Therapeutics (CMMB).
Which stock has performed better over the past year, AEON or CMMB?
CMMB returned -52.96% over the past 12 months, compared with -85.18% for AEON (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and Chemomab Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.